Open Health merges with HEOR and market access firm Pharmeri...

Open Health has joined forces with health economics and outcomes research (HEOR) company Pharmerit International in a move that strengthens its existing market access capabilities.

First Rituxan biosimilar Truxima set to make its debut in US

Takeda nets $660m from product selloff to Germany’s Stada

Shingrix and Trelegy shield GSK from Advair fallout

J&J refutes FDA findings on asbestos in talc

Vyndaqel romps away in US, spurring earnings hike from Pfize...